Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FOLLISTIM AQ vs DANAZOL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Recombinant human follicle-stimulating hormone (FSH) that binds to FSH receptors on granulosa cells in the ovary, stimulating follicular growth and maturation via activation of adenylyl cyclase and increased c AMP production.
Danazol is a synthetic androgen derived from ethisterone that suppresses pituitary-ovarian axis by inhibiting gonadotropin release, leading to decreased estrogen and progesterone levels. It also has weak androgenic and progestational activity.
Ovulation induction in anovulatory women,Development of multiple follicles in assisted reproductive technologies (ART),Controlled ovarian hyperstimulation for in vitro fertilization (IVF),Hypogonadotropic hypogonadism (off-label)
FDA: Treatment of endometriosis, fibrocystic breast disease, hereditary angioedema,Off-label: Idiopathic thrombocytopenic purpura, precocious puberty, gynecomastia
75 to 300 IU subcutaneously once daily for 8 to 14 days, adjusted based on follicular response; maximum daily dose 450 IU and total duration not exceeding 14 days per cycle.
300-600 mg orally twice daily; maximum 800 mg/day
Terminal elimination half-life approximately 24-36 hours (subcutaneous route); clinical context supports daily dosing due to sustained follicular stimulation.
Terminal elimination half-life is 4-4.5 hours; clinical context: requires multiple daily dosing to maintain therapeutic levels.
Metabolized via hepatic and renal pathways; exact enzymes not specified.
Primarily hepatic: undergoes oxidation and conjugation via CYP3A4, with metabolites excreted in urine and feces.
Primarily renal (90%), with intact follitropin alfa/beta and metabolites excreted in urine; biliary/fecal excretion minimal (<10%).
Primarily hepatic metabolism; approximately 60% excreted in feces, 30% in urine as metabolites.
Approximately 60-70% bound to plasma proteins, primarily albumin.
Highly protein bound: 97-99%, primarily to albumin.
Approximately 0.5-1.0 L/kg, indicating distribution primarily into extracellular fluid; limited tissue binding.
Approximately 1.5 L/kg; indicates extensive distribution into tissues, exceeding total body water.
Subcutaneous injection: approximately 70% (relative to IV); intramuscular injection: approximately 60-70%.
Oral bioavailability is approximately 100% due to extensive absorption, but first-pass metabolism reduces systemic availability to about 70-80%.
No formal guidelines; use with caution in moderate to severe renal impairment (e GFR <30 m L/min/1.73 m²) due to limited data; consider lower starting doses based on clinical response.
No adjustment required for GFR ≥10 m L/min; avoid use in GFR <10 m L/min due to fluid retention risk
No formal guidelines; use with caution in Child-Pugh class B or C cirrhosis due to potential altered metabolism; monitor response and consider dose reduction.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated
Not FDA-approved for pediatric use; limited off-label data for anovulatory disorders: start at 75 IU subcutaneously once daily, adjusted per response, based on body weight (1.5-3 IU/kg/day) with careful monitoring.
2-5 mg/kg/dose orally twice daily; maximum 400 mg/day
Not indicated for geriatric use in fertility; no specific dosing recommendations; consider increased risk of adverse events if used off-label; monitor closely.
Start at low end of adult dose, titrate cautiously due to increased risk of fluid retention and thromboembolism
None.
Danazol may cause thrombotic events, including pulmonary embolism and thrombophlebitis. It is contraindicated in patients with a history of thrombosis.
Ovarian hyperstimulation syndrome (OHSS),Ovarian torsion,Multiple pregnancies,Pulmonary embolism,Ovarian enlargement,Ectopic pregnancy,Congenital malformations
Hepatotoxicity (monitor LFTs), pseudotumor cerebri (benign intracranial hypertension), androgenic effects (hirsutism, acne, voice deepening), lipid changes (decreased HDL, increased LDL), thromboembolic events, and premature closure of epiphyses in children.
Hypersensitivity to FSH or excipients,Primary ovarian failure,Ovarian cyst or enlargement of unknown origin,Gynecological cancers (ovarian, breast, uterine),Pregnancy,Uncontrolled thyroid or adrenal dysfunction,Presence of non-gonadal endocrine disorders (e.g., pituitary tumor)
Pregnancy, lactation, porphyria, severe hepatic/renal/cardiac disease, undiagnosed abnormal genital bleeding, history of thromboembolic disorders, androgen-dependent tumors.
No significant food interactions. Maintain a healthy diet; no specific restrictions.
Take with food or milk to minimize gastrointestinal irritation. Avoid grapefruit juice as it may alter drug metabolism. Limit alcohol consumption due to increased risk of hepatotoxicity.
Follistim Aq (follitropin beta) is classified as Pregnancy Category X. It is contraindicated in pregnant women due to the risk of ovarian hyperstimulation syndrome and potential fetal harm. First trimester: No adequate human data, but animal studies show embryotoxicity. Second and third trimesters: Not indicated for use; may cause fetal harm if inadvertently administered during early pregnancy.
Danazol is contraindicated in pregnancy. First trimester exposure is associated with virilization of female fetus including clitoromegaly, labioscrotal fusion, and urogenital sinus abnormalities. Risk in second and third trimesters is also significant due to androgenic effects; fetal growth restriction and preterm birth may occur. No safe gestational period exists.
Excretion into human milk is unknown. Due to the potential for serious adverse reactions in nursing infants, breastfeeding is not recommended during treatment. M/P ratio is not available.
Danazol is excreted in human milk; M/P ratio not determined. Potential for adverse effects in breastfed infant (e.g., androgenization). Use is contraindicated during breastfeeding due to risk of virilization and other hormonal effects.
Not applicable; Follistim Aq is contraindicated during pregnancy. No pharmacokinetic data are available for pregnant women; thus, no dose adjustments are recommended as the drug should not be used in pregnancy.
Danazol is contraindicated in pregnancy; no dose adjustment recommendations exist. If inadvertently used during pregnancy, discontinue immediately and monitor for fetal effects. Pharmacokinetic changes in pregnancy are not studied; dose modifications are not applicable due to contraindication.
Administer subcutaneously; rotate injection sites to avoid lipodystrophy. Do not administer if solution contains particles or discoloration. Use the lowest effective dose to minimize risk of ovarian hyperstimulation syndrome (OHSS). Monitor estradiol levels and ultrasound for follicular development. Discontinue if pregnancy occurs. Store in refrigerator at 2-8°C; do not freeze. Protect from light.
Monitor liver function tests; androgenic effects (acne, hirsutism, voice deepening) may occur; use with caution in patients with cardiac or renal impairment; may potentiate warfarin; effective for hereditary angioedema prophylaxis; check pregnancy test before initiation due to teratogenicity.
Inject exactly as prescribed; do not change dose without consulting your doctor.,Rotate injection sites (abdomen, thigh) to prevent lumps or skin reactions.,Report severe pelvic pain, nausea, vomiting, or rapid weight gain (signs of OHSS) immediately.,Avoid pregnancy during treatment; use barrier contraception until advised by your doctor.,Do not shake the cartridge; gently swirl to mix.,Store in the refrigerator; do not freeze. If unrefrigerated, use within 28 days at room temperature (≤25°C).,Discard any unused solution after the course of treatment.
Do not take if pregnant or planning pregnancy; use effective contraception.,Report symptoms of liver toxicity (jaundice, dark urine, abdominal pain) immediately.,Avoid alcohol as it may increase hepatotoxicity risk.,May cause weight gain, acne, or voice changes; report if bothersome.,Take with food to reduce GI upset.,Use sunscreen due to photosensitivity risk.,Do not discontinue abruptly; taper under medical supervision.
No interactions on record
"Formestane, an aromatase inhibitor, reduces estrogen synthesis, while danazol, a synthetic androgen, possesses weak androgenic and anabolic activity. Concomitant use may lead to additive fluid retention due to danazol's mineralocorticoid-like effects and formestane's potential to cause fluid retention through estrogen withdrawal. This can result in peripheral edema, hypertension, or exacerbation of heart failure in susceptible patients."
"Danazol, a synthetic androgen with weak androgenic activity, may reduce the therapeutic efficacy of vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor used for glycemic control in type 2 diabetes. The proposed mechanism involves danazol-induced activation of cytochrome P450 enzymes (particularly CYP3A4) and potential upregulation of glucagon counter-regulatory pathways, leading to increased vildagliptin clearance and diminished inhibition of DPP-4. Clinically, this interaction may result in elevated postprandial glucose levels and reduced HbA1c reduction, compromising glycemic management."
"Danazol, an androgenic steroid, can induce hepatic microsomal enzymes, particularly CYP2C9, which accelerates the metabolism of glipizide, a sulfonylurea antidiabetic agent. This increased clearance reduces glipizide's plasma concentrations, diminishing its insulinotropic effect and potentially leading to hyperglycemia and loss of glycemic control in patients with type 2 diabetes mellitus."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FOLLISTIM AQ vs DANAZOL, answered by our medical review team.
FOLLISTIM AQ is a Gonadotropin that works by Recombinant human follicle-stimulating hormone (FSH) that binds to FSH receptors on granulosa cells in the ovary, stimulating follicular growth and maturation via activation of adenylyl cyclase and increased c AMP production.. DANAZOL is a Androgen/Antigonadotropin that works by Danazol is a synthetic androgen derived from ethisterone that suppresses pituitary-ovarian axis by inhibiting gonadotropin release, leading to decreased estrogen and progesterone levels. It also has weak androgenic and progestational activity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FOLLISTIM AQ and DANAZOL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FOLLISTIM AQ is: 75 to 300 IU subcutaneously once daily for 8 to 14 days, adjusted based on follicular response; maximum daily dose 450 IU and total duration not exceeding 14 days per cycle.. The standard adult dose of DANAZOL is: 300-600 mg orally twice daily; maximum 800 mg/day. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FOLLISTIM AQ and DANAZOL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FOLLISTIM AQ is classified as Category C. Follistim Aq (follitropin beta) is classified as Pregnancy Category X. It is contraindicated in pregnant women due to the risk of ovarian hyperstimulation syndrome and potential fe. DANAZOL is classified as Category C. Danazol is contraindicated in pregnancy. First trimester exposure is associated with virilization of female fetus including clitoromegaly, labioscrotal fusion, and urogenital sinus. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.